biosimilar


Also found in: Medical, Wikipedia.

bi·o·sim·i·lar

 (bī′ō-sĭm′ə-lər)
adj.
Highly similar in function and effect to an existing biological product, especially to a biologic that has already been clinically tested and approved for use.
n.
A biological product that is biosimilar to an existing product, especially to a biologic.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
M2 PHARMA-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis biosimilar natalizumab
M2 EQUITYBITES-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis biosimilar natalizumab
Global Banking News-September 3, 2019-Polpharma Biologics signs global commercialisation agreement for biosimilar Natalizumab for MS
Fact.MR has announced the addition of the "Pegfilgrastim Biosimilar Market Forecast, Trend Analysis & Competition Tracking - Global Review 2018 to 2028"report to their offering.
Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets.
As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment.
M2 PRESSWIRE-July 29, 2019-: Biosimilar Market Trends Report 2019: EU Guidelines, US Guidelines, Interchangeability, Patent and Patent Dance Issues
Amgen (AMGN) and Allergan (AGN) announced that Mvasi, a biosimilar to Avastin, and Kanjinti, a biosimilar to Herceptin, are now available in the United States.
(Alliance News) - US biopharmaceutical firm Amgen Inc said Thursday two of its biosimilar cancer treatments are now available in the US.
* Biogen's three biosimilar treatments--BENEPALI[TM] (etanercept), FLIXABI[TM] (infliximab) and IMRALDI[TM] (adalimumab)--are estimated to save the European healthcare system 1.8 billion euros in 2019
The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference Lucentis (ranibizumab) and Soliris (eculizumab), respectively, as well as SB3, a biosimilar candidate referencing Herceptin 3 (trastuzumab).